Stockscreener 앱 받기
6.02
3.08%
0.18
시간 외 거래:
6.03
0.01
+0.17%
전일 마감가:
$5.84
열려 있는:
$5.84
하루 거래량:
473.45K
Relative Volume:
0.52
시가총액:
$301.62M
수익:
$124.00K
순이익/손실:
$-49.99M
주가수익비율:
-3.5621
EPS:
-1.69
순현금흐름:
$-31.03M
1주 성능:
-4.29%
1개월 성능:
+14.89%
6개월 성능:
-30.48%
1년 성능:
+9.65%
1일 변동 폭
$5.84
$6.035
1주일 범위
$5.74
$6.40
52주 변동 폭
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
CADL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.02 | 298.61M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 재개 | H.C. Wainwright | Buy |
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Candel Therapeutics CADL 2025Q2 Earnings Preview Downside Ahead on Lack of Revenue Data - AInvest
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
How strong is Candel Therapeutics Inc. company’s balance sheetAchieve explosive financial results today - Jammu Links News
What are the latest earnings results for Candel Therapeutics Inc.Achieve consistent double-digit growth - Jammu Links News
What are Candel Therapeutics Inc. company’s key revenue driversCapitalize on market trends early - Jammu Links News
Is it the right time to buy Candel Therapeutics Inc. stockMaximize profits with strategic stock selection - Jammu Links News
How many analysts rate Candel Therapeutics Inc. as a “Buy”Dynamic investment growth - Jammu Links News
What catalysts could drive Candel Therapeutics Inc. stock higher in 2025Phenomenal returns - Jammu Links News
Candel Therapeutics Inc. Stock Analysis and ForecastUnlock powerful portfolio management tools - Jammu Links News
Is Candel Therapeutics Inc. stock overvalued or undervaluedFree Technical Analysis Support - Jammu Links News
What makes Candel Therapeutics Inc. stock price move sharplyGain the edge with real-time market data - Jammu Links News
Is Candel Therapeutics Inc. a growth stock or a value stockFree Stock Data Feed Backed By Experts - jammulinksnews.com
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Applying Wyckoff theory to Candel Therapeutics Inc. stockTop Gaining Picks With Entry Signals Identified - metal.it
Candel Therapeutics CMO Garrett Buys, Sells Shares Amid Company's Market Performance. - AInvest
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Why Candel Therapeutics Inc. stock attracts strong analyst attentionMomentum Based Equity Trading Plans Reviewed - beatles.ru
Candel Therapeutics to share company update at Canaccord Genuity Growth Conference - Proactive financial news
Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference - Stock Titan
Is Candel Therapeutics Inc. Stock a Good Fit for Conservative InvestorsAI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 16:45:46 - metal.it
What machine learning models say about Candel Therapeutics Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Options Data Show Bullish Bias in Candel Therapeutics Inc.High Conviction Intraday Stock Signals Detected - beatles.ru
How does Candel Therapeutics Inc. generate profit in a changing economyNavigate market shifts with confidence - jammulinksnews.com
What is Candel Therapeutics Inc. company’s growth strategyExceptional market positioning - Jammu Links News
Will Candel Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsTechnical Breakout List - metal.it
What is the dividend policy of Candel Therapeutics Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What are the technical indicators suggesting about Candel Therapeutics Inc.Massive profits - jammulinksnews.com
What drives Candel Therapeutics Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Candel Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
Is Candel Therapeutics Inc. a good long term investmentExplosive returns - PrintWeekIndia
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewswire
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment - citybuzz -
Can Candel Therapeutics Inc. stock recover from recent declineExceptional return forecasts - jammulinksnews.com
Small cap wrap: Blockmate Ventures, Candel Therapeutics, HIVE Digital, American Resources... - Proactive financial news
Candel Therapeutics Gets European Orphan Status for Pancreatic Cancer Drug CAN-2409 - citybiz
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409 - Proactive Investors
Revolutionary Pancreatic Cancer Treatment Shows 31.4-Month Survival, Secures Critical EU Designation - Stock Titan
Candel Therapeutics: Promising Phase 3 Data and Secured Financial Runway Justifies Buy Rating - AInvest
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):